ランキング
価格
はじめての方へ
ログイン
無料体験
米国企業
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS, INC
SGMO
時価総額
$1.4億
PER
マイリストに追加
マイリストに追加
サマリーテーブルに戻る
十億
百万
千
USD
年次
四半期
Download CSV
損益計算書
バランスシート
キャッシュフロー
2011年
12月31日
2012年
12月31日
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net loss
-
-
-
-
-
-
-
-69
-95
-121
-178
-192
-258
Depreciation and amortization
1
1
1
1
1
1
1
2
4
6
9
12
15
Goodwill and Intangible Asset Impairment
-
-
-
-
-
-
-
-
-
-
-
-
89
(Accretion of discount) amortization of premium on marketable securities
-
-
-
-1
-1
-0
1
6
5
1
-3
1
2
Impairment of long-lived assets
-
-
-
-
-
-
-
-
-
-
-
-
66
Amortization and other changes in operating lease right-of-use assets
-
-
-
-
-
-
-
-
-6
-8
-8
-8
-
Depreciation and amortization
1
1
1
1
1
1
1
2
4
6
9
12
15
Stock-based compensation
8
5
6
9
12
15
9
15
19
26
33
32
27
(Accretion of discount) amortization of premium on marketable securities
-
-
-
-1
-1
-0
1
6
5
1
-3
1
2
Gain on free shares
-
-
-
-
-
-
-
-
0
0
0
-
-
Amortization in operating lease right-of-use assets
-
-
-
-
-
-
-
-
-
-
-
-
7
Net (gain) loss on disposal of property and equipment
-
-0
-
-
-
-
-0
-
-0
-0
0
-
-
Deferred income tax benefit
-
-
-
-
-6
-0
-
-
-
-
-
-
-6
Adjustment of CIRM award liability related to termination of the grant
-
-
-
-
-
-
-
-
-
-
6
-
-
Stock-based compensation
8
5
6
9
12
15
9
15
19
26
33
32
27
Other
-
-
-
-
-
-0
-0
-
-
-
-
-
-1
Adjustment of CIRM award liability related to termination of the grant
-
-
-
-
-
-
-
-
-
-
6
-
-
Interest receivable
-0
-0
0
0
-0
-0
0
0
0
0
-1
0
-0
Accounts receivable
1
3
-1
7
-8
2
-2
1
32
-32
1
-2
-3
Prepaid expenses and other assets
0
-0
0
0
-0
1
1
3
7
10
7
5
-6
Accounts payable and other accrued liabilities
-
-
-
4
-1
-2
3
-6
-4
11
-8
13
6
Accrued compensation and employee benefits
0
1
1
-0
-0
0
3
3
4
7
0
1
-13
Deferred revenues
-
-
-
-
-
-
-
99
-36
217
-84
-91
-161
Lease liabilities
-
-
-
-
-
-
-
-
-
-
-
-2
-
Lease liabilities
-
-
-
-
-
-
-
-
-
-
-
-
-5
Other non-current liabilities
-
-
-
-
-
-
-
2
4
1
1
-0
-0
Net cash used in by operating activities
-26
-8
-19
-
-
-
-
37
-144
170
-233
-224
-225
Purchases of marketable securities
113
91
119
228
258
219
252
451
444
571
338
277
60
Maturities of marketable securities
-
-
-
128
338
237
179
392
405
315
603
355
-
Maturities of marketable securities
-
-
-
-
-
-
-
-
-
-
-
-
215
Sales of marketable securities
83
103
51
-
-
-
-
-
-
-
7
2
20
Purchases of property and equipment
1
1
0
1
2
1
4
43
21
15
23
20
21
Purchase of additional Sangamo France shares
-
-
-
-
-
-
-
-
0
1
0
-
-
Net cash provided by investing activities
-20
11
-68
-
-
-
-
-178
-60
-272
248
59
154
At-The-Market Offering
-
-
-
-
-
-
-
-
-
-
27
85
15
Employee Stock
-
-
-
-
-
-
-
-
-
-
3
2
1
Employee Stock
-
-
-
-
-
-
-
-
-
-
3
2
1
Proceeds from issuance of common stock
52
2
9
13
7
1
17
16
2
2
-
-
-
Taxes paid related to net share settlement of equity awards
-
-
2
5
2
1
1
0
0
1
3
2
2
Proceeds from exercise of stock options
-
-
-
-
-
-
-
-
4
9
6
0
-
Net cash provided by financing activities
52
2
76
-
-
-
-
232
142
153
33
85
15
Effect of exchange rate changes on cash and cash equivalents, and restricted cash
-
-
-
-
-
-
-
-
0
-0
-0
1
1
Net (decrease) increase in cash, cash equivalents, and restricted cash
-
-
-
-
-
-
-
91
-62
51
48
-78
-55
Capital Expenditures Incurred but Not yet Paid
-
-
-
-
-
4
-
-
-
-
2
7
0
Buy-out of non-controlling interest
-
-
-
-
-
-
-
-
-
-
1
-
-
Right-of-use assets obtained in exchange for lease obligations
-
-
-
-
-
-
-
-
31
1
10
-
-